California Home
Welcome to California - images of Golden Gate Bridge, ocean sunset, waterfall, flowers, and city skyline
OEHHA Home
Air
About OEHHA
Children's Health
Ecotoxicology
Education
Environmental Indicators
Fish
Pesticides
Proposition 65
Public Information
Risk Assessment
Water
OEHHA E-mail Notification List
Prop. 65 E-mail Notification List
Reference Links
Help!
Site Map
Tell Us What You Think
Contact OEHHA Staff
OEHHA link to home page
 Proposition 65 - Policy and Procedure Documents
Letter from OEHHA to Carcinogen Identification Committee member Thomas Mack regarding Statin Drugs
[05/03/04]

Follow this link to download a copy as a pdf file

Dear Dr. Mack:

The purpose of this letter is to update you on the progress of the Office of Environmental Health Hazard Assessment (OEHHA) in preparing cancer hazard identification documents on each of the statin drugs. As reported at the October 17, 2003 public meeting of the Carcinogen Identification Committee, OEHHA has solicited information relevant to the assessment of the evidence of carcinogenicity of each of the statins by issuing public notices in the California Regulatory Notice Registry (CRNR) and on our Web site at www.oehha.ca.gov. Specifically, OEHHA published a Request for Information on atorvastatin calcium, cerivastatin sodium, fluvastatin sodium, lovastatin, provastatin sodium, and simvastatin in the CRNR on February 21, 2003, and a Request for Information on rosuvastatin calcium in the CRNR on September 26, 2003.

In response to those requests, OEHHA has received information, much of it in the form of summaries or reviews of human and animal studies, on all but one of the statins (no information was submitted on cerivastatin sodium). These submissions included data from rodent studies of atorvastatin calcium and fluvastatin sodium that are not available in the published scientific literature.

OEHHA has also submitted several Freedom of Information Act (FOIA) requests to the U.S. Food and Drug Administration (FDA) on the statins. At this time, OEHHA still awaits FDA responses to FOIA requests for animal carcinogenicity studies of atorvastatin calcium, cerivastatin sodium, fluvastatin sodium, lovastatin, and pravastatin sodium. OEHHA has recently reminded the FDA of these outstanding requests and added a request for the animal carcinogenicity studies for rosuvastatin calcium.

OEHHA continues to gather and evaluate relevant publications on the statins, including epidemiology studies and studies providing information relevant to the mechanism of action. OEHHA anticipates that draft cancer hazard identification documents on all statins will not be available for Committee consideration and deliberation until 2006 at the earliest.

Should you have any questions, please call me.

Sincerely,
[original signed by]

Val F. Siebal
Chief Deputy Director


You will need the free program Adobe Acrobat Reader to view or print PDF files Go to the Adobe web site

For questions regarding Proposition 65, please contact the Cynthia Oshita in the Proposition 65 Implementation Program

For help with this web site please contact the Web Mistress



OEHHA My CA

 Proposition 65 Links


What's New

Current List of Chemicals

Safe Harbor Numbers
(NSRLs/MADLs)

Calendar

General Background

Workshop/Meeting Materials

CRNR Notices

Administrative Listing Mechanisms

State's Qualified Experts Mechanism

Law/Regulations/Rulemaking Activity

Policy and Procedure Documents

Toxicity Criteria Database